Mustafa Diken

List of Publications by Year
in descending order

61 papers	8,740 citations	147801 31 h-index	114465 63 g-index
66 all docs	66 docs citations	66 times ranked	10498 citing authors

#	Article	IF	Citations
1	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature, 2017, 547, 222-226.	27.8	1,806
2	Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature, 2016, 534, 396-401.	27.8	1,243
3	Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature, 2015, 520, 692-696.	27.8	1,030
4	Exploiting the Mutanome for Tumor Vaccination. Cancer Research, 2012, 72, 1081-1091.	0.9	706
5	An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature, 2020, 585, 107-112.	27.8	526
6	Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics, 2014, 15, 190.	2.8	334
7	An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science, 2020, 367, 446-453.	12.6	286
8	Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral Immunity. Cancer Research, 2010, 70, 9031-9040.	0.9	253
9	A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science, 2021, 371, 145-153.	12.6	253
10	HLA typing from RNA-Seq sequence reads. Genome Medicine, 2012, 4, 102.	8.2	204
11	Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3â€² UTRs Identified by Cellular Library Screening. Molecular Therapy, 2019, 27, 824-836.	8.2	191
12	Increased Antigen Presentation Efficiency by Coupling Antigens to MHC Class I Trafficking Signals. Journal of Immunology, 2008, 180, 309-318.	0.8	141
13	Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines. Clinical Cancer Research, 2016, 22, 1885-1896.	7.0	128
14	Nanomedicine and macroscale materials in immuno-oncology. Chemical Society Reviews, 2019, 48, 351-381.	38.1	118
15	Tumor vaccination using messenger RNA: prospects of a future therapy. Current Opinion in Immunology, 2011, 23, 399-406.	5.5	114
16	Specific hepatic delivery of procollagen Î±1(I) small interfering RNA in lipidâ€like nanoparticles resolves liver fibrosis. Hepatology, 2015, 62, 1285-1297.	7.3	101
17	Polymeric Nanoparticles with Neglectable Protein Corona. Small, 2020, 16, e1907574.	10.0	95
18	Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma. Nanomedicine, 2016, 11, 2723-2734.	3.3	82

#	Article	IF	Citations
19	Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Science Translational Medicine, 2021, 13, eabc7804.	12.4	79
20	FLT3 Ligand Enhances the Cancer Therapeutic Potency of Naked RNA Vaccines. Cancer Research, 2011, 71, 6132-6142.	0.9	70
21	Protein coronaâ€“mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses. Journal of Allergy and Clinical Immunology, 2018, 142, 1558-1570.	2.9	60
22	Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice. Cancer Immunology, Immunotherapy, 2016, 65, 1075-1083.	4.2	59
23	HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory. OncoImmunology, 2019, 8, e1629259.	4.6	58
24	Mutanome directed cancer immunotherapy. Current Opinion in Immunology, 2016, 39, 14-22.	5.5	55
25	Tailoring the stealth properties of biocompatible polysaccharide nanocontainers. Biomaterials, 2015, 49, 125-134.	11.4	53
26	SiRNA-mediated in vivo gene knockdown by acid-degradable cationic nanohydrogel particles. Journal of Controlled Release, 2017, 248, 10-23.	9.9	51
27	Mutated tumor alleles are expressed according to their DNA frequency. Scientific Reports, 2014, 4, 4743.	3.3	40
28	mTOR Inhibition Improves Antitumor Effects of Vaccination with Antigen-Encoding RNA. Cancer Immunology Research, 2013, 1, 386-392.	3.4	37
29	Reductive Decationizable Block Copolymers for Stimuli-Responsive mRNA Delivery. Macromolecular Rapid Communications, 2016, 37, 924-933.	3.9	36
30	mRNA: A Versatile Molecule for Cancer Vaccines. Current Issues in Molecular Biology, 2017, 22, 113-128.	2.4	36
31	Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. Cancer Discovery, 2022, 12, 1248-1265.	9.4	36
32	Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics. RNA Biology, 2011, 8, 35-43.	3.1	32
33	A liposomal RNA vaccine inducing neoantigen-specific CD4 ⁺ T cells augments the antitumor activity of local radiotherapy in mice. OncoImmunology, 2020, 9, 1771925.	4.6	32
34	Density of Conjugated Antibody Determines the Extent of Fc Receptor Dependent Capture of Nanoparticles by Liver Sinusoidal Endothelial Cells. ACS Nano, 2021, 15, 15191-15209.	14.6	32
35	Confidence-based Somatic Mutation Evaluation and Prioritization. PLoS Computational Biology, 2012, 8, e1002714.	3.2	30
36	In vivo imaging of the immune response upon systemic RNA cancer vaccination by FDG-PET. EJNMMI Research, 2018, 8, 80.	2.5	28

#	Article	IF	Citations
37	Monitoring Translation Activity of mRNA-Loaded Nanoparticles in Mice. Molecular Pharmaceutics, 2018, 15, 3909-3919.	4.6	27
38	Enhanced protection of C57 BL/6 vs Balb/c mice to melanoma liver metastasis is mediated by NK cells. OncoImmunology, 2018, 7, e1409929.	4.6	26
39	Inducible knockdown of procollagen I protects mice from liver fibrosis and leads to dysregulated matrix genes and attenuated inflammation. Matrix Biology, 2018, 66, 34-49.	3.6	22
40	PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses. Frontiers in Immunology, 2021, 12, 641703.	4.8	21
41	Vaccination with trifunctional nanoparticles that address CD8+dendritic cells inhibits growth of established melanoma. Nanomedicine, 2016, 11, 2647-2662.	3.3	19
42	Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response. OncoImmunology, 2019, 8, e1601480.	4.6	18
43	Antitumor Vaccination with Synthetic mRNA: Strategies for In Vitro and In Vivo Preclinical Studies. Methods in Molecular Biology, 2013, 969, 235-246.	0.9	17
44	Dexamethasone premedication suppresses vaccine-induced immune responses against cancer. OncoImmunology, 2020, 9, 1758004.	4.6	17
45	A non-functional neoepitope specific CD8⁺ T-cell response induced by tumor derived antigen exposure in vivo. OncoImmunology, 2019, 8, 1553478.	4.6	16
46	pH-degradable, bisphosphonate-loaded nanogels attenuate liver fibrosis by repolarization of M2-type macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2122310119.	7.1	16
47	CRISPR/Cas9-mediated TGFÎ²RII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro. Journal of Translational Medicine, 2021, 19, 482.	4.4	14
48	Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer. Cancer Immunology, Immunotherapy, 2022, 71, 1975-1988.	4.2	11
49	FLT3 Ligand as a Molecular Adjuvant for Naked RNA Vaccines. Methods in Molecular Biology, 2016, 1428, 163-175.	0.9	9
50	Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome. Methods in Molecular Biology, 2017, 1499, 223-236.	0.9	9
51	Personalized Neo-Epitope Vaccines for Cancer Treatment. Recent Results in Cancer Research, 2020, 214, 153-167.	1.8	9
52	An Fc-inert PD-L1Ã—4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation. OncoImmunology, 2022, 11, 2030135.	4.6	9
53	Current Developments in Actively Personalized Cancer Vaccination with a Focus on RNA as the Drug Format. Progress in Tumor Research, 2015, 42, 44-54.	0.1	6
54	RNA Vaccination Therapy: Advances in an Emerging Field. Journal of Immunology Research, 2016, 2016, 1-2.	2.2	6

#	Article	IF	Citations
55	Harnessing the potential of noninvasive in vivo preclinical imaging of the immune system: challenges and prospects. Nanomedicine, 2016, 11, 2711-2722.	3.3	6
56	Abstract CT032: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles for potent cancer immunotherapy in patients with malignant melanoma. Cancer Research, 2016, 76, CT032-CT032.	0.9	4
57	Iodine-124 PET quantification of organ-specific delivery and expression of NIS-encoding RNA. EJNMMI Research, 2021, 11, 14.	2.5	3
58	CIMT 2019: report on the 17th Annual Meeting of the Association for Cancer Immunotherapy. Human Vaccines and Immunotherapeutics, 2020, 16, 808-815.	3.3	2
59	Polymeric Nanoparticles: Polymeric Nanoparticles with Neglectable Protein Corona (Small 18/2020). Small, 2020, 16, 2070100.	10.0	2
60	CIMT 2018: Pushing frontiers in cancer immunotherapy â€" Report on the 16th Annual Meeting of the Association for Cancer Immunotherapy. Human Vaccines and Immunotherapeutics, 2018, 14, 2864-2873.	3.3	1
61	CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy. Human Vaccines and Immunotherapeutics, 2022, , 1-10.	3.3	0